[ Inside the business ]

ELV stock analysis

ELV · Elevance Health, Inc.

Hospital and medical service plans. Growing 1%. Keeps 3¢ of every dollar.

Nothing unusual in its latest filings.

The future, in 7 questions

Priced in: 0.2× sales in 5 yrs. Evidence: sales +1% · 3¢ profit/$1.

01 What's priced in?0.2× sales in 5 yrs
Sales now$201.8B
Needed in 5 yrs$34.4B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +1%, steady
No customer over 10%
Sales +1%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 3¢ per $1, falling
'21'22'23'24'253¢
Before running costs: 92% → 89%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −2.7%/yrDebt $30.8B
07 What could break it?1 to watch
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +3%, +1%, then +1% vs. a year ago. New filings show insiders buying.

What could go wrong

Few warning signs.

It has moved 0.8× the market. In the 2008 crisis it fell 57% while the market fell 51%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

3¢ profit.

11¢ to make what it sells, 86¢ on research and overhead, 3¢ left over. Revenue $201.8B in the last 12 months.

Its market

1.0× the economy.

The government expects its industry, insurance carriers, to grow 2.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

10 of 10 years.

Returns beat its 7.1% cost of capital in 10 of the last 10 years. Gross margin went from 100% to 89%.

Future bets

1% on equipment.

$1.1B a year on equipment and buildings.

All figures from Elevance Health, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.